Wuzhou Medical's shares have seen continuous abnormal movement due to a major asset restructuring, with a cumulative deviation of 108.38 percent over four trading days. The company plans to acquire a 100 percent stake in Spintrol Electronic Technology Shanghai, crossing into the high-integration motor control chip sector, while also planning to issue shares to no more than 35 specific investors to raise supporting funds. As of July 27, the company's dynamic price-to-earnings ratio reached 148.86 times, and its static price-to-earnings ratio was as high as 253.74 times, significantly above the average for the medical consumables industry. In recent years, the company's performance has been under pressure, with revenue declining from 534 million yuan in 2023 to 458 million yuan in 2025, and net profit attributable to the parent falling from 60.2651 million yuan to 18.893 million yuan. Industry insiders note that cross-border mergers and acquisitions offer new possibilities for industry growth, but challenges such as cross-industry operational synergy cannot be overlooked.
ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD.Plans to acquire Spintrol Electronic Technology Shanghai, entering chip sector, with share issuance for supporting funds.